علاج مرض الترسب الكثيف مع إيجابية عامل الكلى الكمبلمنتي C3 (C3NeF) وغياب طفرة جين CFH

References

DOI: 10.1681/ASN.2007030356

• The use of rituximab may be justified in patients who are positive for C3NeF, do not have a mutation in CFH, and show evidence of C3 consumption (Figure 4).
• In the presence of C3NeF, removal or dilution of the autoantibody should be considered via plasma exchange or infusion, and anti–B cell agents such as rituximab might be valuable.
• Standard rituximab protocols for the treatment of renal disease should be used, following C3NeF levels and complement assays to document any response.
• The primary criterion for success at the end of this period should be prevention of disease progression (either maintenance of or prevention of decrease in renal function) as measured by the degree of proteinuria/hematuria.
• Secondary criteria for success should be normalization of activity levels of the alternative complement pathway and reduction in C3NeF levels (Figure 4).